The Mucosa of the Small Intestine
暂无分享,去创建一个
[1] P. Watkins,et al. Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[2] P. Gubbins,et al. Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. , 1999, Therapeutic drug monitoring.
[3] D. Greenblatt,et al. Effects of the Antifungal Agents on Oxidative Drug Metabolism , 2000, Clinical pharmacokinetics.
[4] P. Neuvonen,et al. The area under the plasma concentration–time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin , 1998, European Journal of Clinical Pharmacology.
[5] A. Somogyi,et al. Clinical Pharmacokinetics of Cimetidine , 1983, Clinical pharmacokinetics.
[6] S. Krähenbühl,et al. Interaction between grapefruit juice and midazolam in humans , 1995, Clinical pharmacology and therapeutics.
[7] W. Hauck,et al. Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies , 1996, Clinical pharmacology and therapeutics.
[8] K. Inui,et al. Effects of Intestinal and Hepatic Metabolism on the Bioavailability of Tacrolimus in Rats , 1998, Pharmaceutical Research.
[9] F. Russel,et al. Expression and immunolocalization of multidrug resistance protein 2 in rabbit small intestine. , 2000, European journal of pharmacology.
[10] G. Pacifici,et al. (+) and (−) terbutaline are sulphated at a higher rate in human intestine than in liver , 2004, European Journal of Clinical Pharmacology.
[11] D. Shen,et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.
[12] F. Ruschitzka,et al. Acute heart transplant rejection due to Saint John's wort , 2000, The Lancet.
[13] Hiroshi Suzuki,et al. Characterization of the Transport Properties of Cloned Rat Multidrug Resistance-associated Protein 3 (MRP3)* , 1999, The Journal of Biological Chemistry.
[14] I. Pastan,et al. Expression of a multidrug-resistance gene in human tumors and tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[15] U. Christians,et al. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. , 1999, The Journal of pharmacology and experimental therapeutics.
[16] G. Wilkinson,et al. The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. , 1997, Advanced drug delivery reviews.
[17] Jeffrey,et al. Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies. , 1997, Advanced drug delivery reviews.
[18] P. Neuvonen,et al. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole , 1998, Clinical pharmacology and therapeutics.
[19] M. Kool,et al. A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.
[20] P. Watkins,et al. 6′,7′‐Dihydroxybergamottin in grapefruit juice and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4, and P‐glycoprotein , 1999, Clinical pharmacology and therapeutics.
[21] Leslie Z. Benet,et al. Intestinal drug metabolism and antitransport processes : A potential paradigm shift in oral drug delivery , 1996 .
[22] P. Neuvonen,et al. Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride , 1999, Clinical pharmacology and therapeutics.
[23] D. Fleisher,et al. Regulation of Paracellular Absorption of Cimetidine and 5-Aminosalicylate in Rat Intestine , 1999, Pharmaceutical Research.
[24] W. Peters,et al. Cytochromes P-450 in the intestinal mucosa of man. , 1989, Biochemical pharmacology.
[25] P. Neuvonen,et al. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations , 1998, Clinical pharmacology and therapeutics.
[26] T. Baillie,et al. Is the role of the small intestine in first-pass metabolism overemphasized? , 1999, Pharmacological reviews.
[27] J. Hochman,et al. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[28] M. Fromm,et al. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[29] Y Zhang,et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. , 1998, Journal of pharmaceutical sciences.
[30] P. Sonneveld,et al. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. , 2000, International journal of clinical pharmacology and therapeutics.
[31] J. Svanvik. Mucosal blood circulation and its influence on passive absorption in the small intestine. An experimental study in the cat. , 1973, Acta physiologica Scandinavica. Supplementum.
[32] Akira Tsuji,et al. Carrier-Mediated Intestinal Transport of Drugs , 1996, Pharmaceutical Research.
[33] D. Greenblatt,et al. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole , 1999, Clinical pharmacology and therapeutics.
[34] Y Zhang,et al. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. , 1999, Journal of controlled release : official journal of the Controlled Release Society.
[35] U. Klotz,et al. Extrahepatic Metabolism of Drugs in Humans , 1994, Clinical pharmacokinetics.
[36] S. Akiyama,et al. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. , 1997, Cancer letters.
[37] D. Shen,et al. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. , 1997, Advanced drug delivery reviews.
[38] W. Higuchi,et al. Quantitative mechanistic studies in simultaneous fluid flow and intestinal absorption using steroids as model solutes , 1980 .
[39] M Rowland,et al. Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine , 1995, Clinical pharmacology and therapeutics.
[40] H. Saitoh,et al. The secretory intestinal transport of some beta-lactam antibiotics and anionic compounds: a mechanism contributing to poor oral absorption. , 1996, The Journal of pharmacology and experimental therapeutics.
[41] Hans Lennernäs,et al. Jejunal Absorption and Metabolism of R/S-Verapamil in Humans , 1998, Pharmaceutical Research.
[42] R. Oertel,et al. Intestinal secretion of intravenous talinolol is inhibited by luminal R‐verapamil , 1999, Clinical pharmacology and therapeutics.
[43] M. Rowland,et al. Cyclosporin-erythromycin interaction in renal transplant patients. , 1989, British journal of clinical pharmacology.
[44] A. Paterson,et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. , 2000, Pharmacogenetics.
[45] J. Beijnen,et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. , 1997, British Journal of Cancer.
[46] U. Christians,et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine‐treated kidney graft patients after multiple doses , 1997, Clinical pharmacology and therapeutics.
[47] J. Kolars,et al. First-pass metabolism of cyclosporin by the gut , 1991, The Lancet.
[48] H. Rameis. On the interaction between phenytoin and digoxin , 2004, European Journal of Clinical Pharmacology.
[49] S. Grundy,et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. , 1988, The New England journal of medicine.
[50] J. Kolars,et al. Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia , 1992 .
[51] G. Amidon,et al. Drug transport and targeting. Intestinal transport. , 1999, Pharmaceutical biotechnology.
[52] S. Wrighton,et al. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. , 1993, Archives of biochemistry and biophysics.
[53] P. Traber,et al. Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract. , 1992, Gastroenterology.
[54] M. A. Moseley,et al. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[55] P. Beaune,et al. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. , 1990, The Journal of pharmacology and experimental therapeutics.
[56] Patrick J. Sinko,et al. Characterization of the Regional Intestinal Kinetics of Drug Efflux in Rat and Human Intestine and in Caco-2 Cells , 1998, Pharmaceutical Research.
[57] D. Dunbar,et al. Characterization of human small intestinal cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[58] K. Arimori,et al. Transport of theophylline from blood to the intestinal lumen following i.v. administration to rats. , 1985, Journal of pharmacobio-dynamics.
[59] P. Déchelotte,et al. Uptake, 3-, and 6-glucuronidation of morphine in isolated cells from stomach, intestine, colon, and liver of the guinea pig. , 1993, Drug metabolism and disposition: the biological fate of chemicals.
[60] J. Dressman,et al. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. , 1997, Journal of pharmaceutical sciences.
[61] C. Regårdh,et al. Effects of grapefruit juice ingestion – pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men , 1997, European Journal of Clinical Pharmacology.
[62] K. Pang,et al. A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[63] D. Bailey,et al. Interaction of citrus juices with felodipine and nifedipine , 1991, The Lancet.
[64] T. Imai,et al. Species differences in the disposition of propranolol prodrugs derived from hydrolase activity in intestinal mucosa. , 1998, Life sciences.
[65] R. Dubey,et al. Localization and characterization of drug-metabolizing enzymes along the villus-crypt surface of the rat small intestine--II. Conjugases. , 1988, Biochemical pharmacology.
[66] M. Chiba,et al. Metabolism: Scaling-up from In Vitro to Organ and Whole Body , 1994 .
[67] K. Pang,et al. First-pass effect: significance of the intestine for absorption and metabolism. , 1997, Drug and chemical toxicology.
[68] P. Crome,et al. Clinical Pharmacokinetic Considerations in the Elderly , 1989, Clinical pharmacokinetics.
[69] D. Bailey,et al. Erythromycin‐felodipine interaction: Magnitude, mechanism, and comparison with grapefruit juice , 1996, Clinical pharmacology and therapeutics.
[70] Clive G. Wilson,et al. Stool Water Content and Colonic Drug Absorption: Contrasting Effects of Lactulose and Codeine , 1999, Pharmaceutical Research.
[71] A. Melander,et al. Influence of Food Intake on Presystemic Clearance of Drugs , 1983, Clinical pharmacokinetics.
[72] J. Beijnen,et al. Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma – drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study , 1999, Cancer Chemotherapy and Pharmacology.
[73] U. Christians,et al. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. , 1998, The Journal of pharmacology and experimental therapeutics.
[74] P. Crome,et al. Clinical Pharmacokinetic Considerations in the Elderly , 2012 .
[75] D. Shen,et al. Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.
[76] S. Aebi,et al. A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel , 1999, Cancer Chemotherapy and Pharmacology.
[77] D. Fleming,et al. More on rifampin prophylaxis against Haemophilus influenzae b in day-care facilities. , 1988, The New England journal of medicine.
[78] P. Marathe,et al. Absorption and Presystemic Metabolism of Nefazodone Administered at Different Regions in the Gastrointestinal Tract of Humans , 1995, Pharmaceutical Research.
[79] P. Dawson,et al. Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine , 2002, Clinical pharmacology and therapeutics.
[80] J. Falloon,et al. Indinavir concentrations and St John's wort , 2000, The Lancet.
[81] T. Walle,et al. Induction of UDP-Glucuronosyl-Transferase by the Flavonoids Chrysin and Quercetin in Caco-2 Cells , 2004, Pharmaceutical Research.
[82] H K Kroemer,et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.
[83] P. Neuvonen,et al. Grapefruit juice—simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG‐CoA reductase inhibitors , 1998, Clinical pharmacology and therapeutics.
[84] E. Guzman,et al. Torsades de pointes induced by erythromycin and terfenadine. , 1994, The American journal of emergency medicine.
[85] D. Mailman. Effects of vasoactive intestinal polypeptide on intestinal absorption and blood flow. , 1978, The Journal of physiology.
[86] M. Ducharme,et al. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice , 1995, Clinical pharmacology and therapeutics.
[87] W. H. Barr,et al. Intestinal drug absorption and metabolism. II. Kinetic aspects of intestinal glucuronide conjugation. , 1970, Journal of pharmaceutical sciences.
[88] J. Noordhoek,et al. Prediction of intestinal first-pass effect of phenacetin in the rat from enzyme kinetic data--correlation with in vivo data using mucosal blood flow. , 1982, Biochemical pharmacology.
[89] J. Kolars,et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.
[90] H. Saitoh,et al. Restricted Intestinal Absorption of Some β-Lactam Antibiotics by an Energy-Dependent Efflux System in Rat Intestine , 1997, Pharmaceutical Research.
[91] Y. Sai,et al. Nonlinear intestinal absorption of 5-hydroxytryptamine receptor antagonist caused by absorptive and secretory transporters. , 1997, The Journal of pharmacology and experimental therapeutics.
[92] P. Watkins,et al. Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[93] P. Richardson,et al. Intestinal blood flow. , 1980, Gastroenterology.
[94] W. L. Chiou,et al. First-Pass Accumulation of Salicylic Acid in Gut Tissue After Absorption in Anesthetized Rat , 1995, Pharmaceutical Research.
[95] J. Bond,et al. Intestinal villus blood flow measured with carbon monoxide and microspheres. , 1976, The American journal of physiology.
[96] D. Fleisher,et al. Drug, Meal and Formulation Interactions Influencing Drug Absorption After Oral Administration , 1999, Clinical pharmacokinetics.
[97] K. Tew,et al. ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[98] P. Lévy,et al. Torsades de Pointes after treatment with terfenadine and ketoconazole. , 1992, European heart journal.
[99] Brahma N. Singh. Effects of Food on Clinical Pharmacokinetics , 1999, Clinical pharmacokinetics.
[100] S. Krähenbühl,et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. , 1998, British journal of clinical pharmacology.
[101] L. Benet,et al. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction , 1992, Clinical pharmacology and therapeutics.
[102] K. Pang,et al. Route-Dependent Metabolism of Morphine in the Vascularly Perfused Rat Small Intestine Preparation , 2000, Pharmaceutical Research.
[103] A. Duncan,et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.
[104] Hébert. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. , 1997, Advanced drug delivery reviews.
[105] P. Watkins,et al. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. , 1987, The Journal of clinical investigation.
[106] Morton B. Brown,et al. Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine , 1997, Clinical pharmacology and therapeutics.
[107] L. Benet,et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole , 1997, Clinical pharmacology and therapeutics.
[108] F. Guengerich. Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. , 1997, Chemico-biological interactions.
[109] I. Pastan,et al. Multidrug resistance in human cancer. , 1992, Critical reviews in oncology/hematology.
[110] P. Neuvonen,et al. Itraconazole greatly increases plasma concentrations and effects of felodipine , 1997, Clinical pharmacology and therapeutics.
[111] R. Benton,et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram , 1996, Clinical pharmacology and therapeutics.
[112] I. Roots,et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) , 1999, Clinical pharmacology and therapeutics.
[113] A. Schinkel,et al. The physiological function of drug-transporting P-glycoproteins. , 1997, Seminars in cancer biology.
[114] D. Shen,et al. First‐pass metabolism of midazolam by the human intestine , 1996, Clinical pharmacology and therapeutics.
[115] A. S. Gross,et al. Influence of grapefruit juice on cisapride pharmacokinetics , 1999, Clinical pharmacology and therapeutics.
[116] P. Neuvonen,et al. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid , 1998, Clinical pharmacology and therapeutics.
[117] D. Grant,et al. The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. , 1997, Mutation research.
[118] R. Minchin,et al. Metabolism of drugs and other xenobiotics in the gut lumen and wall. , 1990, Pharmacology & therapeutics.
[119] L. Benet,et al. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.
[120] D. Bailey,et al. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics , 1993, Clinical pharmacology and therapeutics.
[121] R. Evers,et al. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. , 1996, The Journal of clinical investigation.
[122] I. Tamai,et al. Carrier-mediated approaches for oral drug delivery , 1996 .
[123] L. Benet,et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine , 1995, Clinical pharmacology and therapeutics.
[124] J. Kolars,et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. , 1994, Drug metabolism and disposition: the biological fate of chemicals.
[125] Y. Sawada,et al. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects , 2000, Clinical pharmacology and therapeutics.
[126] J. Wagner. Propranolol: Pooled Michaelis‐Menten parameters and the effect of input rate on bioavailability , 1985, Clinical pharmacology and therapeutics.
[127] P. Watkins,et al. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. , 1997, Advanced drug delivery reviews.